It is known from breast cancer that ERBB2 overexpressing tumours respond well to chemotherapy, especially in combination with a taxane-based agent and an anti HER2-antibody, currently being the established neoadjuvant chemotherapy regime [16,27]. Here, ERBB2 is linked to neoplasm.